Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes.
clinical outcomes
immunohistochemistry
lymphocytes
memory T cells
prognosis biomarkers
prostate cancer
regulatory T cells
tumor immune cell infiltration
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
18
01
2024
accepted:
13
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
epublish
Résumé
The localization, density but mostly the phenotype of tumor infiltrating lymphocytes (TIL) provide important information on the initial interaction between the host immune system and the tumor. Our objective was to assess the prognostic significance of T (CD3 Immunohistochemistry (IHC) was used to assess the infiltration of CD3 TIL subtypes were present at different densities in the tumor, tumor margin and adjacent normal-like epithelium, but their density and phenotype in the tumor area were the most predictive of clinical outcomes. In multivariate analyses, a high density of T These results show that the proportion of T
Identifiants
pubmed: 38887294
doi: 10.3389/fimmu.2024.1372837
pmc: PMC11180786
doi:
Substances chimiques
Forkhead Transcription Factors
0
Biomarkers, Tumor
0
FOXP3 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1372837Informations de copyright
Copyright © 2024 Molina, LaRue, Simonyan, Hovington, Vittrant, Têtu, Fradet, Lacombe, Bergeron and Fradet.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Mod Pathol. 2018 Oct;31(10):1539-1552
pubmed: 29849114
Front Public Health. 2022 Feb 16;10:811044
pubmed: 35252092
Clin Cancer Res. 2017 Nov 15;23(22):6863-6874
pubmed: 28790115
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
Cell Mol Life Sci. 2020 Oct;77(19):3693-3710
pubmed: 32006051
Eur J Cancer. 2020 Nov;140:105-118
pubmed: 33075623
Mod Pathol. 2013 Mar;26(3):448-55
pubmed: 23041830
Front Immunol. 2023 Jun 26;14:1205266
pubmed: 37435060
J Pathol. 2021 Oct;255(2):155-165
pubmed: 34255349
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
Oncoimmunology. 2020 Oct 13;9(1):1832324
pubmed: 33194318
Prostate. 2021 Jan;81(1):50-57
pubmed: 32986884
Cancers (Basel). 2020 Jun 12;12(6):
pubmed: 32545454
Front Immunol. 2020 Jul 28;11:1633
pubmed: 32849557
BMC Cancer. 2013 May 25;13:258
pubmed: 23705594
Front Immunol. 2022 May 02;13:864497
pubmed: 35585972
Vet Q. 1989 Oct;11(4):222-31
pubmed: 2690456
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
J Oral Pathol Med. 2019 Oct;48(9):788-798
pubmed: 31323145
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Prostate. 2014 Oct;74(14):1452-61
pubmed: 25111810
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Cancers (Basel). 2023 Jan 08;15(2):
pubmed: 36672367
Eur Urol Focus. 2019 Mar;5(2):192-196
pubmed: 28753812
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Sci Rep. 2019 Sep 19;9(1):13579
pubmed: 31537872
J Immunol. 2010 Apr 15;184(8):4317-26
pubmed: 20231690
Prostate. 2003 May 15;55(3):187-93
pubmed: 12692784
Clin Cancer Res. 2016 Jan 1;22(1):158-66
pubmed: 26253870
Cell Oncol (Dordr). 2019 Jun;42(3):343-356
pubmed: 30825183
J Urol. 2018 Mar;199(3):683-690
pubmed: 29203269
Clin Cancer Res. 2020 Jan 15;26(2):332-339
pubmed: 31413009
Cancer Cell. 2023 Mar 13;41(3):374-403
pubmed: 36917948
Eur Urol. 2019 Mar;75(3):498-505
pubmed: 30181068
Prostate. 2021 Jan;81(1):20-28
pubmed: 33085799
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Curr Opin Urol. 2019 Nov;29(6):612-619
pubmed: 31469662
Eur J Cancer. 2013 Apr;49(6):1273-9
pubmed: 23266046
Cancer. 2020 Jan 15;126(2):260-270
pubmed: 31691957
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Curr Top Microbiol Immunol. 2017;410:29-45
pubmed: 28929191
Cancer Biol Ther. 2016 Nov;17(11):1213-1220
pubmed: 27791459
Br J Cancer. 2004 Aug 2;91(3):541-3
pubmed: 15266325
APMIS. 2012 Nov;120(11):901-8
pubmed: 23009114
Eur Urol. 2023 Aug;84(2):191-206
pubmed: 37202314
J Cancer Res Clin Oncol. 2019 Dec;145(12):3105-3114
pubmed: 31562550
Prostate. 2019 Jun;79(9):969-979
pubmed: 30999388
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
Prostate Cancer Prostatic Dis. 2024 Jun;27(2):192-201
pubmed: 37679602
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Anticancer Res. 2005 Nov-Dec;25(6C):4435-8
pubmed: 16334122
Ann N Y Acad Sci. 2018 Apr;1417(1):104-115
pubmed: 29566262
Clin Cancer Res. 2021 Jan 15;27(2):380-382
pubmed: 33199495
Tumour Biol. 2017 Jul;39(7):1010428317716628
pubmed: 28681697
Int J Cancer. 2019 Jun 15;144(12):3099-3110
pubmed: 30537104
Front Immunol. 2020 May 15;11:940
pubmed: 32499786